10-K: Dermata Therapeutics Files 10-K, Provides Update on Clinical Programs and Financial Position

Dermata Therapeutics reports its 2024 financial results and provides an update on the clinical development of its lead product candidates, XYNGARI and DMT410, including the ongoing Phase 3 trial for acne and a collaboration with Revance for hyperhidrosis.

Summary

• Dermata Therapeutics, a late-stage medical dermatology company, filed its 10-K report for the fiscal year ended December 31, 2024.
• The company is focused on developing and commercializing innovative pharmaceutical product candidates for skin diseases and aesthetic applications.
• Their lead product candidate, XYNGARI, is in Phase 3 clinical trials for the treatment of moderate-to-severe acne, with top-line results expected in March 2025.
• XYNGARI is a once-weekly topical treatment utilizing Spongilla technology, derived from a freshwater sponge.
• The company is also developing DMT410, another Spongilla-based product, for topical delivery of botulinum toxin, with a Phase 2 clinical trial planned in collaboration with Revance Therapeutics for axillary hyperhidrosis.
• The company reported a net loss of $12.3 million for 2024, compared to a net loss of $7.8 million in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of $3.2 million, which is expected to fund operations into the third quarter of 2025.
• The company will need to raise additional capital to continue its clinical development programs and commercialization efforts.
• The company is subject to risks related to the development, regulatory approval, and commercialization of its product candidates, competition, and intellectual property protection.
• The company is also subject to risks related to its dependence on third parties for manufacturing and clinical trials.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and collaborations, the increasing net loss and the need for additional capital raise concerns. The going concern warning from the auditor further dampens the sentiment.

Positives

• XYNGARI has shown promising results in a Phase 2b study, demonstrating a 45% reduction in inflammatory lesions after four treatments.
• The company has an exclusive supply agreement for Spongilla raw material, ensuring a reliable source for its product candidates.
• The company has a Clinical Trial Collaboration Agreement with Revance Therapeutics to explore the use of XYNGARI with DAXXIFY for the topical treatment of axillary hyperhidrosis.
• The company is actively seeking partnerships to further develop its DMT410 program for aesthetic skin conditions.

Negatives

• The company has incurred losses since inception and anticipates that it will continue to incur losses for the foreseeable future.
• The company has a limited operating history and has not generated any revenue from product sales.
• The company will require additional capital to fund its operations and continue to support its planned development and commercialization activities.
• The reports of the independent registered public accounting firm for the fiscal years ended December 31, 2024 and 2023 contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's business is dependent on the successful development, regulatory approval, and commercialization of its product candidates, in particular XYNGARI and DMT410.
• The company may experience failures of or delays in clinical trials which could jeopardize or delay its ability to obtain regulatory approval and commence product sales.
• The company faces intense competition from both brand and generic companies which could limit its growth and adversely affect its financial results.
• The company is subject to extensive governmental regulation and faces significant uncertainties and potentially significant costs associated with its efforts to comply with applicable regulations.
• The company may not be able to develop or maintain sales capabilities or effectively market or sell any products that it may successfully commercialize.
• Manufacturing or quality control problems may damage the company's reputation, require costly remedial activities, or otherwise negatively impact its business.
• The company's profitability will depend on coverage and reimbursement by third-party payors, and healthcare reform and other future legislation may lead to reductions in coverage or reimbursement levels.
• The company currently, and may in the future need to, license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
• The company may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect its ability to develop, manufacture and market its products and product candidates.
• The raw material for the company's product candidates, XYNGARI and DMT410, is derived from naturally occurring ingredient that grow only in limited areas that need to be harvested annually.
• The company currently relies on a third party for the raw materials needed for XYNGARI and DMT410, and if it encounters any difficulties in accessing or procuring alternative sources on acceptable terms, or at all, its business may suffer.
• The company's current licensed patents covering XYNGARI expired between 2022 and 2023, which was prior to its anticipated date for any market launch.
• If the company fails to comply with its obligations under any of its third-party agreements, it could lose license rights that are necessary to develop its product candidates.
• The company's directors, executive officers and certain stockholders own a significant percentage of its common stock and, if they choose to act together, will be able to exert significant control over matters subject to stockholder approval.
• The company will need to add personnel, which will increase the size and complexity of its organization and it may experience difficulties executing growth and corporate strategies.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues clinical development of XYNGARI and DMT410. The company will need to raise additional capital to fund its operations and continue to support its planned development and commercialization activities.

Management Comments

• Management believes that existing cash, together with interest thereon, will be sufficient to fund operations into the third quarter of 2025.

Industry Context

The company operates in the competitive medical and aesthetic pharmaceutical industries, facing competition from pharmaceutical companies, generic drug companies, biotechnology companies, cosmetic companies, and academic and research institutions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention several competitors, including LEO Pharma, Journey Medical, VYNE Therapeutics, Galderma, Sun Pharmaceuticals Ltd., Sol-Gel, Arcutis Biotherapeutics, Arena Pharmaceuticals, Amgen, AbbVie, Bristol Meyers Squib, and Pfizer Inc.
• These companies are all major players in the dermatology market, and Dermata will need to compete effectively against them to achieve commercial success.

Related Party Transactions

• Sean Proehl, the son of Gerald T. Proehl, our Chief Executive Officer, is currently employed as our Associate General Counsel.
• Certain related persons, including Gerald T. Proehl, our Chief Executive Officer and Mary Fisher, member of our Board of Directors, participated in the January 2025 Private Placement.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures if the company is unable to raise additional capital.
• Patients may benefit from the successful development and commercialization of the company's product candidates.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• Receive top-line results from the STAR-1 Phase 3 trial in March 2025.
• Initiate the second XYNGARI Phase 3 clinical trial (STAR-2) upon adequate financing.
• Continue the partnership with Revance for the DMT410 program in hyperhidrosis and aesthetic skin conditions.
• Complete a Phase 2 trial of XYNGARI for the treatment of psoriasis, subject to obtaining additional financing and/or a strategic partner.
• Acquire or in-license additional dermatology programs to the portfolio.
• Maximize the value of the portfolio by partnering with companies for commercialization in territories throughout the world.
• Further strengthen the intellectual property portfolio, path to new chemical entity (NCE) exclusivity, raw material supply and advance regulatory filings.

Key Dates

Keywords

XYNGARI, DMT410, acne, psoriasis, hyperhidrosis, Spongilla, clinical trials, dermatology, Revance, DAXXIFY, FDA, botulinum toxin, pharmaceutical, medical, aesthetic